저자: Dave · 외국인
요약 보기
Molina Healthcare(MOH)는 메디케이드·마켓플레이스 의료비 급증으로 2025 EPS 가이던스가 24.5→19→14달러로 하향됐고 주가는 60% 이상 하락했다. 마이클 버리가 매수했지만 발표자는 기술적 하락 추세(베어 플래그)를 근거로 바닥은 아직 아니라고 본다. 시나리오 적정가는 베어 77달러, 베이스 112달러, 불 160달러이며 베어 확률을 45%로 가장 높게 잡았다. 135·110·95달러 지지선을 주시하라고 언급했다. 면책 고지가 포함되어 있다.
다듬은 글
What's up, value hunters? Dave here, and today we're diving deep into Molina Healthcare, ticker MO. This stock has taken an absolute beating, down over 60% from its highs, and it's got some big names like Michael Bur taken a peak. But the real question is, has Mo finally found its bottom, or is there more pain ahead?
Let's find out. All right, let's set the stage. The market narrative for Molina Healthcare is pretty clear. It's a story of significant headwinds. We're seeing persistent medical cost inflation hitting them hard, especially in their marketplace business. This led to a pretty dramatic slash in their 2025 earnings guidance, going from an initial $24.50 all the way down to a projected $14 per share.
Ouch. Despite all this operational pain and that huge stock price decline, there's a contrarian twist. The legendary Michael Bur has actually invested in Mo. So, we've got a tugof-war between fundamental challenges and a famous value investors bet. The big question is who's right? For those unfamiliar, Molina Healthcare, Inc.
is a managed health care giant primarily serving low-income families and individuals through government sponsored programs like Medicaid and Medicare, plus the state insurance marketplaces. They're a big player, serving about 5.2 2 million members across 18 states. Now, remember that earnings guidance I mentioned?
They started 2025 expecting $24.50 per share. Then it dropped to $19 and now they're saying $14. That's a huge shift, and it tells you everything you need to know about the challenges they're facing with those rising medical costs outpacing state reimbursement rates. So, how do we reconcile a company slashing guidance with a famous investor buying in?
Well, we crunch the numbers with our scenario analysis. First, the markets definitely priced in a lot of that negative news, but Bur's bet suggests he sees long-term value beyond the immediate pain. Let's break down our three scenarios. First up, the base case. Here, we're assuming Molina largely meets that revised 2025 EPS guidance of $14.
The market has kind of digested the medical cost inflation news, and we're betting management's efforts to renegotiate skate rates and improve efficiency will give them some stability. The core Medicaid business should hold up reasonably well despite costs creeping up faster than rate increases. We assigned this a reasonable forward PE of 8.0x, giving us a fair value of $112.
We're giving this base case a 40% probability, mainly because while things are tough, the stock is currently testing its first support at $135, which could provide a temporary floor, but it's not a strong reversal signal. Next, we have the bullcase. This is where Molina really shines and beats expectations.
Maybe medical cost inflation cools off faster or they get much better state reimbursement rates or their marketplace segment turns around dramatically. Michael Barry's move points to this long-term potential. In this scenario, we're projecting an optimistic EPS of $16 and applying a higher PE of 10.0X, bringing our fair value to $160.
We're only giving this bull case of 15% probability. Why so low? Because for the stock to truly enter an uptrend, our technicals tell us it needs to maintain above $25, which is significantly above current prices. That's a big hurdle, meaning a fundamental positive catalyst would need to be huge. And finally, the bare case.
This is where medical cost inflation just keeps getting worse, impacting Medicaid more, or the marketplace segments losses grow beyond projections. Management could miss their already reduced 2025 guidance. We're looking at a conservative EPS of $11 and a lower PE of 7.0x 0x due to increased risk, giving us a fair value of $77.
We're giving this bare case the highest probability at 45%. And here's why. The technical analysis strongly supports this pessimistic outlook. The stock is in a clear downtrend, gapping down and forming a bare flag. If that 135 support level fails, we're looking at significant downside risks towards 110 and even $95.
The markets lost confidence and the charts are screaming caution. All right, let's pull up the chart. Here's what I'm seeing based on our technical analysis. Mo has been in a definitive downtrend and it's gapped down significantly. Currently, it looks like it's forming a bare flag pattern, which typically signals a continuation of the downtrend.
Looking at key levels, we have support at $135, then $110, and if things get really ugly, $95. For this stock to even think about resuming an uptrend, it needs to decisively maintain above $25. That's a long way up from where we are, indicating a pretty steep climb for the bulls. So, is the bottom in for Molina Healthcare?
Based on our analysis and with a heavy lean on those technicals and persistent cost pressures, my verdict is not yet. The bare case has the highest probability at 45% driven by the potential for continued medical cost inflation and those overwhelmingly bearish technical indicators like the downtrend and bare flag.
While Michael Bur's bet is intriguing, he might be a bit early on this one. The path of least resistance right now still looks to be down. For those looking to potentially get in, given our scenario fair values and the technical supports, I'd be looking for potential levels of interest around the $110 and $95 technical support zones.
Our barecase fair value is 77. So keep that in mind as a potential floor if things really get rough. Remember, these are just potential entry points, not guarantees. All right, value hunters, that's our deep dive into MA. If you found this analysis helpful, smash that like button, subscribe for more episodes, and drop a comment below.
What do you think about Molina Healthcare? Are you with Bur or do you see more downside? Let me know. This video is forformational and educational purposes only and is not financial advice. Investing involves risks and you could lose money. Always do your own research and consult with a qualified financial professional before making any investment decisions. I am not a financial adviser.
Comments 0